Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 (Vaxneuvance) followed by PNEUMOVAX 23 in adults at risk for pneumococcal disease
NCT03547167Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2018
- Primary completion
- Jan 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13 at 5 days, Percentage of Participants With Solicited Systemic Adverse Events Following V114 or Prevnar 13 at 14 days and 2 more. Started Jul 2018; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03547167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547167.